Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GRI

- PMLiVE

Harnessing commercial innovation

Novo Nordisk’s Christian Kanstrup on meeting challenges head-on and preparing for an era of launches

- PMLiVE

Abbott diabetes sensor wins European CE mark

FreeStyle Libre system gains kitemark

Novo Nordisk adds to board of directors

Brian Daniels elected to join the board

- PMLiVE

Merck and Sun Pharma part company on branded generics

Will continue partnership on diabetes and inflammatory disorder projects

- PMLiVE

Lantus sales decline as competition heats up at Sanofi

Brand affected by biosimilars, growth of other new drugs and pricing pressure

- PMLiVE

Tresiba safer than insulin glargine, says Novo Nordisk

Trial compares its basal insulin with Sanofi's Lantus

- PMLiVE

Novo Nordisk files improved haemophilia B therapy in EU

Nonacog beta pegol is due to be submitted to US regulators in the next few months

Sanofi reception

Sanofi uses priority review voucher for diabetes combo

LixiLan in race with Xultophy in bid to hit US market first

- PMLiVE

Nucala price far too high for US market, says ICER

Concludes GlaxoSmithKline's new severe asthma therapy is not value for money

Eli Lilly HQ

Lilly’s Lantus ‘follow-on’ approved in the US

Basaglar is first insulin product to be licensed via the FDA's truncated 505(b)(2) pathway

- PMLiVE

Novo Nordisk will work with IBM on diabetes care

Development of digital platform to help diabetics and their doctors manage their illness

Eli Lilly HQ

Lilly says insulin peglispro too risky to pursue

Discontinues development of medicine once tipped as a diabetes blockbuster

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links